Mycophenolate Sodium Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 180mg , 360 mg
Reference Brands: Myfortic®(EU&US)
Category:
Nephrology
Mycophenolate Sodium Tablets are immunosuppressive medications used in nephrology to prevent organ rejection in kidney transplant patients. Marketed under the brand name Myfortic® in the US and EU, they offer a delayed-release formulation to reduce gastrointestinal side effects while ensuring effective immune suppression.
Mycophenolate Sodium is available in Tablet
and strengths such as 180mg , 360 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mycophenolate Sodium is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mycophenolate Sodium can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mycophenolate Sodium Tablets are widely used in nephrology to prevent organ rejection in kidney transplant patients. This immunosuppressive agent, known for its delayed-release formulation, reduces gastrointestinal side effects while maintaining therapeutic efficacy. It is commonly marketed under the brand name Myfortic® in both the US and EU. Mycophenolate Sodium works by inhibiting the proliferation of T and B lymphocytes, crucial for immune response control post-transplantation. Ideal for inclusion in Pharma B2B nephrology product portfolios, these tablets offer high-quality, GMP-compliant manufacturing for global partners. Source Mycophenolate Sodium Tablets today to meet demand in renal care and transplant immunosuppression therapies. Mycophenolate Sodium Tablets are widely used in nephrology to prevent organ rejection in kidney transplant patients. This immunosuppressive agent, known for its delayed-release formulation, reduces gastrointestinal side effects while maintaining therapeutic efficacy. It is commonly marketed under the brand name Myfortic® in both the US and EU. Mycophenolate Sodium works by inhibiting the proliferation of T and B lymphocytes, crucial for immune response control post-transplantation. Ideal for inclusion in Pharma B2B nephrology product portfolios, these tablets offer high-quality, GMP-compliant manufacturing for global partners. Source Mycophenolate Sodium Tablets today to meet demand in renal care and transplant immunosuppression therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing